1/112
Looks like no tags are added yet.
what signifies mild-moderate UC
4-6 stools/day, minimal symptoms
what type of UC can be treated with enemas
left sided disease
which type of UC can be treated with suppositories
proctitis
how to treat extensive UC disease
requires systemic treatment
first line treatment for mild-mod active UC
oral and/or topical ASAs (combo more effective)
what to do if pt is unresponsive to standard dose 5-ASA
high dose mesalamine plus rectal mesalamine OR budesonide
what is considered mod-severe active UC
4-6 stools per day, +/- blood in stool, some systemic symptoms
induction treatment options
systemic corticosteroids, TNF inhibitors, biologics, newer small molecules
new induction and maintenance options for mod-severe UC
TNF inhibitors, anti-integrin, IL12/23 inhibitors, JAK inhibitors, S1P inhibitors
recommendation for mod-severe active UC if infliximab is used
combination therapy with thiopurine
rule with thiopurine treatment for mod-severe active UC
thiopurine monotherapy should NOT be used for induction, only an option for maintenance
MTX use for treatment of UC
should NOT be used for induction or maintenance
what characterizes severe-fulminant UC
6-10 BMs/day, blood present, systemic symptoms, requires inpatient treatment
what to use in severe UC in patients first and if they are unresponsive
parenteral corticosteroids, consider TNF inhibitors or cyclosporine if pts are unresponsive
maintenance of remission for UC
choice depends on what was used to induce remission
no role for steroids
ASAs, TNF inhibitors, biologic, purines, newer small molecule
recommendation for patients who are on a biologic for remission that failed 5-ASA previously
recommend AGAINST continuing 5-ASA
ASA recommendations for treating mild-mod active CD
sulfasalazine marginally effective, mesalamine derivatives have minimal efficacy and are not recommended
other first line options for mild-mod active CD
controlled release budesonide, diet based strategies
treatment for mod-severe active CD
systemic corticosteroids (maybe IV if hospitalized), early biologic or advanced therapy may be beneficial
can use in mod-severe CD patients who are failing immunosuppressive treatment or steroid dependent pts
TNF inhibitors (infliximab preferred)
what makes TNF inhibitors more effective for CD
combination therapy with AZA or maybe MTX
immunomodulator monotherapy not recommended to induce remission but may help to maintain remission once induced
AZA and 6-MP
drugs that should NOT be used for mod-severe CD
cyclosporine, 5-ASA, sulfasalazine
treatment for severe-fulminant CD
parenteral corticosteroids, infliximab
AZA and 6-MP
MTX
TNF inhibitors
anti-integrin (vedolizumab only)
IL12/23 inhibitors
JAK inhibitor
what drugs may exacerbate IBD
NSAIDs + antibiotics
goal of therapy for IBD
inducing and maintaining remission
what to avoid in remission
corticosteroids
nutrition support for IBD
-"Complete bowel rest" using PN (not necessarily required.)
-Enteral nutrition may temper inflammatory process and be steroid sparing and is preferred over PN.
-supplement nutritional deficiencies (vitamins + minerals)
what IBD type is surgery more useful for and why
UC, can be curative
why is surgery in CD less useful
it can reappear elsewhere in the GI tract
main biologics used in IBD
anti-TNF agents, anti-alpha integrins, IL-12/23, JAK + SIP inhibitors
ASA agents used for IBD, which one is active
sulfasalazine + 5-ASA (mesalamine)= active component
how to avoid ADRs caused by sulfasalazine
can administer mesalamine alone
formulations of mesalamine and which is more effective
topical, suppository, oral
topical is more effective than oral
allergy that can cause hypersensitivity to sulfasalazine
sulfa allergy
monitoring for sulfasalazine
CBC and LFTs at baseline then every other week for 3 months, monthly for next 3 months + BUN/SCr periodically
drug interactions with sulfasalazine and what is the risk
antiplatelet/anticoagulants/NSAIDs- may increase bleeding risk
common ADRs with ASA agents
nausea, vomiting, headache
what to do if pt has reaction to sulfasalazine
give mesalamine
when are corticosteroids used for IBD
used for induction of remission, not for maintenance
local corticosteroids
rectal hydrocortisone
budesonide
drug interactions w budesonide
CYP3A inhibitors may increase systemic exposure (ketoconazole, grapefruit juice)
systemic corticosteroids
oral prednisone/ prednisolone
IV methylprednisolone
when else can steroids be used besides induction of remission
disease flares
long term ADRs w systemic corticosteroids
osteoporosis/ bone issues, growth failure, HPA suppression, obesity, cataracts
how to combat bone ADRs w corticosteroids
give calcium + vitamin D
consider bisphosphonates
reserved for pts who fail 5-ASA/ steroid treatment, used in conjunction with other drugs
azathiprine and mercaptopurine
treatment duration w AZA/6-MP and what part of treatment is it used for
extended periods to maintain remission, limited role in induction
ADRs w AZA/6-MP
stomatitis, bone marrow suppression, hepatotoxicity
what to check for before giving 6-MP to avoid ADRs
TPMT
cyclosporine use
effective in inducing remission in patients with refractory UC who do not respond to steroids
duration of treatment of cyclosporine
not long term, used as bridge therapy
ADRs of cyclosporine
nephrotoxicity
neurotoxicity
metabolic
GI upset, gingival hyperplasia, hirsutism
monitoring for cyclosporine
BP, BUN/SCr, LFTs
drug interactions with cyclosporine
substrate for CYP3A and pgp
use for methotrexate and why
can be used in CD to assist in inducing remission because of steroid sparing effects
ADRs of MTX
bone marrow suppression, stomatitis, mucositis, cirrhosis, teratogenic
supplement to give with MTX and why
folic acid due to bone marrow suppression
CI of MTX
pregnancy, chronic liver disease, immunodeficiency
monitoring with MTX
CBC, SCr, LFTs
TNF-a antagonists used for for UC and CD
infliximab, adalimumab
TNF-a antagonist used for UC only
golimumab
TNF-a antagonist used for CD only
certolizumab
MOA of natalizumab and vedolizumab
block leukocyte trafficking
indication of natalizumab vs vedolizumab
natalizumab: CD
vedolizumab: UC and CD
IL-12/23 inhibitors used for UC and CD
Ustekinumab, risankizumab, mirikizumab, guselkumab
JAK inhibitors used for IBD and their specific indications
tofacitinib: UC
upadacitinib: UC and CD
S1P inhibitors and their specific indications
ozanimod: UC
estrasimod: UC
role of TNF-a antagonists in IBD
induction and maintenance
pros and cons of combination therapy with TNF antagonists and immunosuppressives
increased efficacy but also increased ADR risk
which TNF-a antagonist is given IV infusion instead of SQ
infliximab
TNF-a inhibitors ADRs
serious infection risk
injection site reaction
risk of malignancy
risk of demyelinating disease
may exacerbate CHF
hepatotoxicity
how to avoid serious infections for TNF inhibitors
avoid with active infection, ensure vaccines up to date, tuberculin test/ hepatitis B/C, no live vaccines for 3 months after treatment
type of malignancy associated with TNF inhibitors
lymphoma
who is at risk for demyelinating disease from TNF inhibitors
pts with a history of cancer, optic neuritis, or pre-existing neurologic disease
monitoring for TNF inhibitors
CXR, PPD, s/s of infection, UA, CBC, SCr, LFTs, Hep B/C
what can occur in the body with treatment of TNF inhibitors what decreases treatment response and potentially increase the risk of infection
development of antibodies to treatment
what to do if anti-drug antibodies (ADAs) develop with TNF inhibitors
escalate dose, decrease dosing interval, therapeutic drug monitoring (TDM)
anti-a subunit of integrins used for CD to induce and maintain remission
natalizumab
when is natalizumab used and when should it not be used
use in pts who fail/don't tolerate TNF inhibitors
NOT to be combined with immunosuppressants or TNF-a inhibitors
when to d/c natalizumab
in patients with no benefit by 12 weeks and/or who are still steroid dependent within 6 months
main ADR/ concern with natalizumab
associated with PML (untreatable CNS disorder related to opportunistic viral infection)
what virus is associated with PML and how to test for it
JC virus, test for JC antibody
pts at increased risk for PML with natalizumab use
longer duration of therapy, prior immunosuppressant use, JC antibody positive
anti-a4B7 integrin antibody used for UC and CD
vedolizumab
route of administration for vedolizumab
IV until week 6, then can start SQ q2weeks
ADRs with vedolizumab
infection, hypersensitivity rxn, ADAs, NO PML risk
difference in route of administration in IL12/23 inhibitors for induction vs maintenance and which one is different
IV induction, SQ maintenance
guselkumab can be IV or SQ for induction
ADRs of IL-12/23 inhibitors
hypersensitivity rxn, ADAs, potential hepatotoxicity
ADR specific to ustekinumab
rapidly developing cutaneous cell carcinoma, possible neurotoxicity (RPLS and PRES)
monitoring for IL-12/23 inhibitors
CXR, PPD, lipids, LFTs (!!!), renal fnc, infection, skin (ustekinumab)
reason for TDM of biologics and when to use
potential for determining concentrations of drugs and ADAs
use if loss of treatment response (reactive TDM)
issue with TDM of biologics
optimal trough concentrations not clear- moving target!
what to do if there are detectable ADAs and sub-therapeutic drug levels after a serum TDM is done
change to alternate drug within the same class
what to do if there are not detectable ADAs but sub-therapeutic drug levels after a serum TDM is done
dose escalate
what to do regardless of ADAs if there is therapeutic drug levels after a serum TDM is done but the patient is experiencing treatment failure
switch to out of class biologic agent
JAk inhibitor approved for UC only to use in pts who have an inadequate response to TNF blockers
tofacitinib
selective JAK1 inhibitor used for UC and CD in pts who cannot use TNF blockers
upadacitinib
combo use rule with JAk inhibitors
should NOT be used with immunosuppressants or biologics
black box warnings for JAK inhibitors
increased mortality and thrombosis in pts greater than 50y/o with at least one CV risk factor + malignancies